Table 1.
Patient and treatment characteristics
| Sex, n (%) | |
| Male | 53 (50%) |
| Female | 54 (50%) |
| Age, median (range), y | 70 (30-95) |
| Ethnicity, n (%) | |
| Non-Hispanic | 61 (57%) |
| Hispanic | 38 (36%) |
| Other/unknown | 8 (7%) |
| Primary cancer site,∗ n (%) | |
| Breast | 28 (26%) |
| Prostate | 27 (25%) |
| Lung | 14 (13%) |
| Gynecologic | 7 (7%) |
| Head and neck | 6 (6%) |
| Hematologic | 4 (4%) |
| Other | 23 (21%) |
| Interval from last RT to COVID-19 testing, n (%) | |
| <1 mo | 10 (9%) |
| 1 mo to 1 y | 18 (17%) |
| 1-5 y | 35 (33%) |
| >5 y | 44 (41%) |
| Mean lung radiation therapy dose, median (range) | 0.2 Gy (0-16.6 Gy) |
| Mean lung radiation therapy dose, n (%) | |
| 0 Gy | 52 (49%) |
| 0-4 Gy | 30 (28%) |
| >4 Gy | 25 (23%) |
Abbreviations: COVID-19 = Coronavirus Disease 2019; RT = radiation therapy.
∗
Two patients had head and neck cancer and a second primary cancer diagnosis (lung, prostate).